Semi-Annual Report — FY2026 H1
What CellSeed Inc. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-14View the original on EDINET
How much it says
46Typical
What moved here
13named for the first time
Its own wording
32terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, revenue was ¥20.820 million, operating loss was ¥570.958 million, and interim net loss was ¥610.611 million. The Cell Sheet Regenerative Medicine Business, including CLS2901C, continued its Phase 3 trial, and joint research agreements with Tokyo Women's Medical University and a memorandum of understanding with the National Center for Child Health and Development concerning the provision of specimens are in place. In addition, financing was obtained through the exercise of the 25th Series Stock Acquisition Rights, and cash and cash equivalents at period-end stood at ¥1,792.266 million.
Komori's summary of this document, not the document's own words.46Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
49
Typical
75
Very detailed
0
Almost nothing
0
Almost nothing
55
Typical
31
Thin
53
Typical
55
Typical
50
Typical
R&D spend4億円Money spent making new things.
Cash left over-6億円Cash from the business, less what went into equipment.
Spent on equipment46百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.